Boehringer/Lilly's linagliptin demonstrates durable efficacy over two years

Results of a 102 week Phase III study for linagliptin (trade named Trajenta in Europe and Tradjenta in the USA), from independent German drugmaker Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY), show meaningful and durable reductions in blood glucose for adults with type 2 diabetes.

In the two-year study presented at the  the Annual Meeting of the European Association for the Study of Diabetes (EASD) last week, the DPP-4 inhibitor linagliptin showed a favourable safety profile and lowered HbA1c levels by 0.8% over the long term in those patients treated with linagliptin for the full study period.

"These results show that the efficacy achieved by linagliptin is reliable and meaningful in a clinical setting, but also that it is durable over the long term. This is especially important in chronic conditions such as type 2 diabetes," commented David Owens, Clinical Professor of the Department of Medicine, Cardiff University School of Medicine, Wales, UK.